Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$120.9B | 6.2 | $114.6 21.5% undervalued | 14.7% | $33.2B | $5,467.0M | 2.7% | 16.5% | 52.7% | 7.4% | 53.6% | |
$242.4B | 7.0 | $174.5 24.5% undervalued | 19.2% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$154.5B | 6.7 | $34.2 67.4% overvalued | 55.5% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$150.5B | 6.6 | $305.1 22.7% overvalued | 12.0% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 14.6% | 28.4% | |
$43.4B | 6.1 | $54.1 24.2% overvalued | (18.0%) | $5,872.6M | $502.2M | 0.9% | 8.6% | 77.8% | 25.8% | 7.4% | |
$34.9B | 7.0 | $43.1 49.8% overvalued | (29.7%) | $4,033.0M | $453.9M | 11.3% | 11.3% | 60.4% | 21.7% | 120.3% | |
$24.7B | 5.3 | $65.0 146.8% undervalued | 34.0% | €18.0B | €274.0M | (0.8%) | 1.5% | 43.1% | (4.2%) | 63.4% | |
$21.9B | 6.2 | $199.6 10.4% overvalued | (3.8%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 1.9% | |
$21.6B | 5.9 | $181.2 72.0% undervalued | (15.3%) | $5,655.4M | $1,132.4M | (23.5%) | 20.0% | 64.3% | 4.5% | 43.0% | |
$19.4B | 7.9 | $134.5 50.7% overvalued | 62.5% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 29.7% | 6.9% | |
$13.6B | 6.0 | $190.0 8.5% undervalued | (43.2%) | $3,999.0M | $622.7M | 3.5% | 15.6% | 70.3% | 14.2% | 2.3% |
As of today, Medtronic plc has a stock rating of 6 (out of 10), which is considered Good.
As of today, Medtronic plc has a Good stock rating, which is 21.5% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.